Previous studies reported that several inflammatory mediators, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-17 (IL-17), engage in the NAFLD process of development as well as progress. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.